(November 25, 2020, Hong Kong) Kintor Pharmaceutical Limited (stock code: 9939.HK, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) announced that the clinical trial of Proxalutamide in the treatment of COVID-19 (see FDA clinical trials website: ClinicalTrials.gov, trial no.: NCT04446429) was based on the positive results preliminarily shown in the treatment of male subjects. The Company has included female subjects, and planned to recruit 168 subjects. The recruitment has already been launched.

168 female subjects will be respectively included in the “Proxalutamide + standard care” experimental arm and receive the “Placebo + standard Care” comparator arm based on a ratio of 2:1. Ivermectin + azithromycin are used as standard care in this study. The endpoints of the clinical trial include the percentage of subjects hospitalized for COVID-19, duration of remission the severity of symptoms (including 26 clinical symptoms ranging from mild fever to anosmia).

Dr. Tong Youzhi, founder, chairman and CEO of Kintor Pharmaceutical said, “we are pleased to see that Proxalutamide has shown positive preliminary results in clinical trials for the treatment of COVID-19. We have high expectation on the efficacy and safety of Proxalutamide and hope to provide new solutions for patients with COVID-19”.